Browse
Submit Data
Databases
API
Help

Dataset Information

0 Views

0 Connections

0 Citations

0 Reanalyses

0 Downloads

Omics score: 0

MHC-I immunopeptidome profiling of macrophage-derived antigen depots (MAtigens)

ABSTRACT: This project presents the comprehensive MHC-I immunopeptidomic profiling of macrophage-derived antigen depots (MAtigens) to demonstrate their capability for antigen enrichment and the generation of a biologically optimized antigen repertoire. To validate this cross-species, mass spectrometry-based proteomics was performed on two distinct experimental sets. The murine cohort comprises unmodified macrophages (M), murine tumor cells (BO), and their corresponding engineered MAtigens (M@BO). The human clinical cohort includes human macrophages (M), patient-derived tumor cells (PDC, specifically pancreatic ductal adenocarcinoma), and the resulting human MAtigens (M@PDC). By identifying and comparing the presented MHC-I peptides across these groups, this dataset provides critical evidence that the MAtigen platform effectively internalizes and optimizes tumor-specific antigens for enhanced presentation.

ORGANISM(S): Homo Sapiens Mus Musculus

SUBMITTER: Jianxin Wang

PROVIDER: PXD080706 | iProX | Tue Jul 07 00:00:00 BST 2026

REPOSITORIES: iProX

ACCESS DATA

Json Xml

Similar Datasets

IFN-γ-STAT1 Axis Drives MHC-II Antigen Presentation Potentiation in Tumor Associated Macrophages

Project description:While the IFN-γ-STAT1 signaling pathway is well-characterized in promoting MHC class II (MHC-II)-dependent antigen presentation within pro-inflammatory macrophages during acute infections, its functional dynamics in tumor-associated macrophages (TAMs) remain poorly understood. Here, we systematically investigated the immunomodulatory role of IFN-γ-STAT1 axis in TAMs through integrative bioinformatics and experimental validation. Transcriptomic analysis of tumor-infiltrating myeloid cells across multiple cancer cohorts revealed a strong correlation between STAT1 activation and MHC-II pathway enrichment, particularly in IFN-γ-high TAM subsets. To mechanistically dissect this relationship, we employed bone marrow-derived macrophages (BMDMs) polarized under tumor-conditioned media and subjected them to IFN-γ stimulation. Single-cell RNA sequencing demonstrated that IFN-γ triggered STAT1 nuclear translocation, upregulating MHC-II genes. Our findings establish IFN-γ-STAT1 as a master regulator of TAM immunogenicity, proposing targeted STAT1 activation as a strategy to overcome myeloid-driven immunosuppression in cancer.

2026-02-22 | GSE293728 | GEO

Identification of antigens presented by MHC for vaccines against tuberculosis

Project description:The immune response against tuberculosis relies, at least in part, on CD4+ T cells. Protective vaccines require the induction of antigen-specific CD4+ T cells via mycobacterial peptides presented by MHC class-II in infected macrophages. We have purified MHC class-I and MHC-II peptides and analysed them by mass spectrometry. We have successfully identified 97 mycobacterial peptides presented by MHC-II and 54 presented by MHC-I, from 76 and 41 antigens, respectively. The sequences of selected peptides were confirmed by spectral match validation and immunogenicity evaluated by IFN-gamma ELISpot against peripheral blood mononuclear cells from volunteers vaccinated with BCG, M.tb latently infected subjects or patients with tuberculosis disease. Three antigens were expressed in viral vectors, and evaluated as vaccine candidates alone or in combination in a murine aerosol M.tb challenge model. When delivered in combination, the three candidate vaccines conferred significant protection in the lungs and spleen compared with BCG alone, demonstrating proof-of-concept for this unbiased approach to identifying novel candidate antigens.

2020-01-08 | E-MTAB-8057 | biostudies-arrayexpress

Quantitative cell type specific immunopeptidome analysis during macrophage and tumor co-evolution reveals therapeutic MHC-I restricted peptides in glioblastoma

Project description:Glioblastoma treatment by immunotherapy is limited by the immunosuppresive tumor microenvironment, in part created by GBM associated macrophages. To uncover targetable MHC-I peptides for targeted immunotherapy, we performed cell type specific immunopeptidome analysis on primary macrophages and GBM tumor cells in a co-culture system to profile antigen presentation at the tumor:macrophage interface. Profiling the MHC-I restricted peptides revealed systematic antigen presentation alteration in both GBM tumors and macrophages during their co-evolution. We selected co-culture induced significantly altered peptides (CIVS peptides) which can serve as potential immunotherapy targets, and developed an mRNA vaccine encoding six selected CIVS peptides from GAMs and GBM tumor cells. Two doses of mRNA vaccination generated antigen specific immune response, significantly delayed GBM tumor growth, and in some cases eradicated tumor, demonstrating the translational potential of CIVS peptides as therapeutic targets for GBM/GAM targeting vaccines.

2025-09-03 | PXD057588 | Pride

Reshaping of the MHC-I ligandome in response to reovirus-based cancer immunotherapy

Project description:Oncolytic viruses (OVs), known for their cancer-killing characteristics, overturn tumor-associated defects in antigen presentation through the MHC class I pathway and induce protective neo antitumor CD8 T cell responses. Nonetheless, whether OVs shape the tumor MHC-I ligandome remains unknown. Here, we investigated if an OV induces the presentation of novel MHC I-bound tumor antigens (termed tumor MHC-I ligands). Using comparative mass spectrometry (MS)-based MHC-I ligandomics, we determined differential tumor MHC-I ligand expression following treatment with oncolytic reovirus in a murine ovarian cancer model. In vitro we found that reovirus induces the presentation of tumor MHC-I ligands in cancer cells. Concurrent multiplexed quantitative proteomics revealed that the changes in tumor MHC-I ligand presentation were mostly independent of reovirus-induced alterations of their source proteins. In an in vivo model, tumor MHC-I ligands were induced by reovirus in tumors but also, more importantly, analysis of spleens (a source of antigen-presenting cells) showed exclusive induction of most MHC-I ligands occurred in tumor-bearing mice. Finally, IFNγ assays demonstrated immunogenicity of the reovirus-induced MHC-I ligands. OV-induced MHC-I responses may be exploited in combinatorial approaches to promote the efficacy of cancer immunotherapies.

2019-05-20 | PXD013066 | Pride

Genome-wide Screens Identify Lineage- and Tumor-Specific Genes Modulating MHC-I- and MHC-II-Restricted Immunosurveillance of Human Lymphomas [DLBCL_GSK126]

Project description:Tumors frequently subvert MHC class I (MHC-I) peptide presentation to evade CD8+ T cell immunosurveillance, though how this is accomplished is not always well-defined. To identify the global regulatory networks controlling antigen presentation, we employed genome-wide screening in human diffuse large B cell lymphomas (DLBCLs). This approach revealed dozens of genes that positively and negatively modulate MHC-I cell surface expression. Validated genes clustered in multiple pathways including cytokine signaling, mRNA processing, endosomal trafficking, and protein metabolism. Genes can exhibit lymphoma subtype- or tumor-specific MHC-I regulation, and a majority of primary DLBCL tumors displayed genetic alterations in multiple regulators. We established SUGT1 as a major positive regulator of both MHC-I and MHC-II cell surface expression. Further, pharmacological inhibition of two negative regulators of antigen presentation, EZH2 and thymidylate synthase, enhanced DLBCL MHC-I presentation. These and other genes represent potential targets for manipulating MHC-I immunosurveillance in cancers, infectious diseases, and autoimmunity.

2020-11-02 | GSE160609 | GEO

Genome-wide Screens Identify Lineage- and Tumor-Specific Genes Modulating MHC-I- and MHC-II-Restricted Immunosurveillance of Human Lymphomas [DLBCL_RNAseq]

2020-11-02 | GSE160608 | GEO

Single-cell ATAC sequencing of SIINFEKL-reactive T cells in GL261 murine brain tumors in MHC class II deficient tumor-mircoenvironments

Project description:Single cell ATAC sequencing of SIINFEKL-reactive immune cell from intracranial murine GL261-SIINFEKL tumors 20 days after inoculation. SIINFEKL-reactive T cells were sorted based on dextramer staining. We show that loss of major histocompatibility complex (MHC) class II (MHCII)-restricted antigen presentation on bbm drives dysfunctional intratumoral tumor-reactive CD8+ T cell states through increased chromatin accessibility and expression of Tox, a critical regulator of T cell exhaustion.

2023-01-11 | E-MTAB-12512 | biostudies-arrayexpress

Longitudinal scRNA-Seq of immune cells from GL261 murine brain Tumors and MHC class II deficient tumor-mircoenvironments

Project description:Longitudinal phenotyping of T cells and myeloid cells in early (day 14) and late (day26) GL261 tumors. Single cell RNA sequencing of CD45+ immune cell from intracranial murine GL261-SIINFEKL tumors 20 days after inoculation. SIINFEKL-reactive T cells were sorted based on dextramer staining. Using time-resolved scRNA-seq of murine tumor-infiltrating immune cells from early (d14) and late stage (d26) syngeneic GL261 gliomas we observed constant MHCII expression by murine microglia over time and overall high but decreasing MHCII expression in late stage bbm indicating a dynamic process of MHCII expression. We show that loss of major histocompatibility complex (MHC) class II (MHCII)-restricted antigen presentation on bbm drives dysfunctional intratumoral tumor-reactive CD8+ T cell states through increased expression of Tox, a critical regulator of T cell exhaustion. By calculating the normalized abundance of T cell states along the pseudotime trajectory of SIINFEKL-reactive CD8+ T cells retrieved from myeloidMHCII-proficient and -deficient microenvironments, we found an enrichment of a distinct T cell state in myeloidMHCIIKO CD8+ T cells that was defined by peak expression of exhaustion markers. Mechanistically, MHCII-dependent activation of CD4+ T cells restricts myeloid-derived osteopontin that triggers a chronic activation of nuclear factor of activated T cells (Nfat)2 in tumor-reactive CD8+ T cells. In summary, we provide evidence that MHCII-restricted antigen presentation on bbm is a key mechanism to directly maintain functional cytotoxic T cell states in brain tumors.

2023-01-19 | E-MTAB-12523 | biostudies-arrayexpress

Extracellular vesicles from Pseudomonas aeruginosa suppress MHC-related molecules in human Lung Macrophages

Project description:We investigate whether EVs secreted from P. aeruginosa alter MHC antigen expression in lung macrophages, thereby potentially contributing to decreased pathogen clearance.

2020-08-03 | GSE142801 | GEO

MHC I-restricted immunopeptidomics analysis of human monocyte-derived macrophages exposed to biological nanoparticles bearing influenza hemagglutinin

Project description:In this study, primary human monocyte-derived macrophages were exposed to plant-derived virus-like particles (VLPs) bearing influenza A hemagglutinin (HA) or soluble influenza HA, as control. Immunopurified MHC class I-associated peptides were analysed by nano-flow high pressure liquid chromatography coupled to high-resolution dopant-assisted electrospray ionisation mass spectrometry. A total of 109 host-derived MHC I peptides were identified in the VLP-treated samples, two of which were also detected in controls. The peptides unique to VLP treatment were, on average, ~13 amino acid residues long, more basic and hydrophilic, and were mainly processed via proteolysis by matrix metalloproteinases and cathepsins. The proteins associated with these peptides were primarily involved in cellular, metabolic and regulatory processes and activated several pathways including inflammation stimulation and attenuation, response to stimuli, innate and adaptive immunity, clathrin-mediated endocytosis, protein synthesis and endo-lysosomal degradation. This study is the first report to describe the response of a primary human antigen-presenting cell to nanoparticulate vs. soluble antigen exposure from an immunopeptidomics point of view.

2022-02-24 | PXD010741 | Pride

OmicsDI is part of the ELIXIR infrastructure

OmicsDI is an Elixir interoperability service. Learn more ›

Tweets

OmicsDI Databases

PRIDE
PeptideAtlas
MassIVE
JPOST Repository
Physiome Model Repository

EGA
EVA
ENA
LINCS
PAXDB
Cell Collective

MetaboLights
Metabolomics Workbench
MetabolomeExpress
GNPS
BioModels
FAIRDOMHub

ArrayExpress
dbGaP
ExpressionAtlas
GEO
NODE

Information

Databases
Help
API
Contact us
Code on GitHub
Terms of use
Submit Data